1. "2017"
Formats
  1. Journal Article (3053)
  2. Meeting Abstract (1581)
  3. Book Section (242)
  4. Conference Paper (35)
  5. Book Whole (12)
  6. Editorial (1)
  7. Review (1)
Groups
  1. Department of Medicine (2037)
  2. GSK Faculty (1130)
  3. Solid Tumor Oncology Division (1105)
  4. Sloan Kettering Institute Postdocs (1022)
  5. Surgery (893)
  6. Survivorship Research (780)

More Groups

People
  1. Sergio Giralt (86)
  2. Jose Baselga (68)
  3. Michael Berger (67)
  4. Monica Morrow (65)
  5. Jedd Wolchok (62)
  6. Martin Tallman (61)

More People

Years
  1. 2017 (4925)
Publications
  1. Journal of Clinical Oncology (349)
  2. Blood (233)
  3. Annals of Oncology (123)
  4. International Journal of Radiation Oncology, Biology, Physics (122)
  5. Modern Pathology (85)
  6. Laboratory Investigation (76)

More Publications

Publishers
  1. Elsevier Inc. (599)
  2. Springer (383)
  3. American Society of Clinical Oncology (378)
  4. Nature Publishing Group (310)
  5. Oxford University Press (280)
  6. American Society of Hematology (246)

More Publishers

Results (4925)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term survival in patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab
    Meeting Abstract

    Topalian, S. L.; Hodi, F. S.; Brahmer, J. R.; Gettinger, S. N.; Smith, D. C.; McDermott, D. F.; Powderly, J. D.; Sosman, J. A.; Atkins, M. B.; Spigel, D. R.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two phase 1 trials
    Meeting Abstract

    Carvajal, R.; Sato, T.; Shoushtari, A. N.; Sacco, J.; Nathan, P.; Orloff, M.; Corrie, P.; Steven, N.; Evans, J.; Infante, J.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Investigating the kynurenine pathway as a central effector mechanism of tumor immune-suppression and its potential as therapeutic target
    Meeting Abstract

    Campesato, L. F.; Budhu, S.; Zhang, X. M.; Manfredi, M. G.; McGovern, K.; Wolchok, J. D.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Heat-inactivated modified vaccinia virus Ankara (MVA) as vaccine adjuvant
    Meeting Abstract

    Yang, N.; Shuman, S.; Merghoub, T.; Wolchok, J.; Deng, L.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • The checkpoint inhibitor TTI-621 (SIRPαFc) stimulates innate and adaptive immune responses in patients with hematologic and solid tumor malignancies
    Meeting Abstract

    Johnson, L.; Ansell, S.; Chen, R.; Flinn, I.; Maris, M.; O'Connor, O.; Lesokhin, A.; Thompson, J.; Akilov, O.; Querfeld, C.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Pre-existing T cell immunity, mutational burden and stromal TGF-β signaling drives clinical responses to atezolizumab in locally advanced or metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Mariathasan, S.; Turley, S. J.; Nickles, D.; Wang, Y.; Kadel, E. E. 3rd; Koeppen, H.; Yuen, K.; Castiglioni, A.; Astarita, J. L.; Cubas, R.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Pooled 3-year overall survival data from phase II and phase III trials of nivolumab (NIVO) combined with ipilimumab (IPI) in advanced melanoma
    Meeting Abstract

    Postow, M.; Larkin, J.; Wolchok, J.; Chiarion-Sileni, V.; Hodi, F. S.; Rutkowsk, P.; Grob, J. J.; Grossmann, K.; Schadendorf, D.; Chesney, J.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • ENCORE-601: Phase 1b/2 study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Gandhi, L.; Johnson, M. L.; Opyrchal, M.; Ramalingam, S.; Janne, P.; Chachoua, A.; Ordentlich, P.; Brouwer, S.; Sankoh, S.; Schmidt, E.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • A phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced melanoma (MEL), renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Meric-Bernstam, F.; Gordon, M.; Tykodi, S.; Lam, E.; Vaishampayan, U.; Chaves, J.; Nikolinakos, P.; Fan, A.; Lee, R.; McDermott, D.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Clinical activity of adenosine 2A receptor (A2AR) inhibitor CPI-444 is associated with tumor expression of adenosine pathway genes and tumor immune modulation
    Meeting Abstract

    Hotson, A.; Powderly, J.; Emens, L.; Forde, P.; Hellman, M.; Fong, L.; Markman, B.; Hughes, B.; Goldman, J.; Sznol, M.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save